Which diabetes drug wins for heart failure? 26,000-Patient study aims to find out
NCT ID NCT06980623
First seen Dec 16, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study compares two popular diabetes medications, tirzepatide and semaglutide, in 26,000 adults with type 2 diabetes and a specific type of heart failure (preserved ejection fraction). The goal is to see which drug better reduces the risk of hospitalization for heart failure or death. Participants are already taking one of the two drugs as part of their routine care, and researchers will track their health outcomes over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.